ライフサイエンスコーパス: parainfluenza virus 5

1 1 (IFIT1) is the principal antiviral ISG for parainfluenza virus 5.

2 sequence, FPIV, important for the budding of parainfluenza virus 5.

3 NASEK was dispensable for viruses, including parainfluenza virus 5 and Coxsackie B virus, that enter

4 athogens: human respiratory syncytial virus, parainfluenza virus 5, and Sendai virus.

5 ructed chimeras containing the ectodomain of parainfluenza virus 5 F (PIV5 F) and either the MPER, th

6 Here we report the crystal structure of the parainfluenza virus 5 F protein in its prefusion conform

7 ess the functional role of the paramyxovirus parainfluenza virus 5 F protein TM domain, alanine scann

8 Here, a soluble form of parainfluenza virus 5 F was triggered to refold using te

9 rystal structure of a fragment of the simian parainfluenza virus 5 fusion protein (SV5 F), revealing

10 , we show that the FP from the paramyxovirus parainfluenza virus 5 fusogenic protein, F, forms an N-t

11 ng globular head domain of the paramyxovirus parainfluenza virus 5 HN protein is entirely dispensable

12 usion activation, F activation involving the parainfluenza virus 5 HN stalk domain, and properties of

13 Knockdown of IFIT1 restored parainfluenza virus 5 infection in IFN-alpha-pretreated,

14 By modeling the crystal structure of parainfluenza virus 5 into the density, it is shown that

15 The paramyxovirus parainfluenza virus 5 mediates membrane merger through i

16 t robust maturation following infection with parainfluenza virus 5 or influenza virus.

17 hat Cav-1 colocalizes with the paramyxovirus parainfluenza virus 5 (PIV-5) nucleocapsid (NP), matrix

18 Parainfluenza virus 5 (PIV5) activates and is neutralize

19 For the paramyxoviruses parainfluenza virus 5 (PIV5) and mumps virus, M-NP inter

20 Proline substitution in this region of HN of parainfluenza virus 5 (PIV5) and Newcastle disease virus

21 erent VLP production platforms, one based on parainfluenza virus 5 (PIV5) and the other based on Nipa

22 Using parainfluenza virus 5 (PIV5) as a model system, we show

23 rmined the structure of the L-P complex from parainfluenza virus 5 (PIV5) at 4.3- angstrom resolution

24 In this work, we generated a recombinant parainfluenza virus 5 (PIV5) containing NP from H5N1 (A/

25 The paramyxovirus parainfluenza virus 5 (PIV5) enters cells by fusion of t

26 Here, we optimized a vaccine candidate, parainfluenza virus 5 (PIV5) expressing the SARS-CoV-2 S

27 igh similarity to the structure of prefusion parainfluenza virus 5 (PIV5) F, with the main structural

28 Because only the prefusion structure of the parainfluenza virus 5 (PIV5) F-trimer is available, to s

29 MR spectroscopy, we show that the TMD of the parainfluenza virus 5 (PIV5) fusion protein adopts lipid

30 ucts were coexpressed with the nonhomologous parainfluenza virus 5 (PIV5) fusion protein, indicating

31 Parainfluenza virus 5 (PIV5) HN exists as a noncovalent

32 Parainfluenza virus 5 (PIV5) is a member of the Paramyxo

33 Parainfluenza virus 5 (PIV5) is a promising viral vector

34 Parainfluenza virus 5 (PIV5) is a prototypical paramyxov

35 Parainfluenza virus 5 (PIV5) is an appealing vector for

36 Parainfluenza virus 5 (PIV5) is an enveloped, single-str

37 The P protein of parainfluenza virus 5 (PIV5) is an essential cofactor of

38 Parainfluenza virus 5 (PIV5) is thought to contribute to

39 To investigate the role of NP protein in parainfluenza virus 5 (PIV5) particle formation, NP prot

40 ation of copyback DVGs readily occurs during parainfluenza virus 5 (PIV5) replication, but that their

41 In this work, we tested a recombinant parainfluenza virus 5 (PIV5) strain expressing the glyco

42 serendipitously identified a viral mRNA from parainfluenza virus 5 (PIV5) that activates IFN expressi

43 Preparations of parainfluenza virus 5 (PIV5) that are potent activators

44 quence variation of 16 different isolates of parainfluenza virus 5 (PIV5) that were isolated from a n

45 unable to be recognized by measles virus and parainfluenza virus 5 (PIV5) V proteins were tested in s

46 We tested the recombinant parainfluenza virus 5 (PIV5) vectors expressing RSV glyc

47 he threonine residue at position 286 of P of parainfluenza virus 5 (PIV5) was found phosphorylated.

48 The V proteins of measles virus (MV) and parainfluenza virus 5 (PIV5) were introduced into HFLC u

49 rotein (prefusion form) of the paramyxovirus parainfluenza virus 5 (PIV5) WR isolate was determined.

50 Parainfluenza virus 5 (PIV5), a paramyxovirus, is not kn

51 Similar results were also observed with parainfluenza virus 5 (PIV5), a paramyxovirus, when neut

52 Here we show that vaccination with parainfluenza virus 5 (PIV5), a promising live viral vec

53 Infection by parainfluenza virus 5 (PIV5), a prototypical member of t

54 The genome of parainfluenza virus 5 (PIV5), a prototypical paramyxovir

55 Parainfluenza virus 5 (PIV5), a prototypical paramyxovir

56 V), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5 (PIV5), all members of the genus R

57 During the replication of parainfluenza virus 5 (PIV5), copyback defective virus g

58 Parainfluenza virus 5 (PIV5), formerly known as simian v

59 y, papaverine also inhibited paramyxoviruses parainfluenza virus 5 (PIV5), human parainfluenza virus

60 that a porcine isolate of the paramyxovirus parainfluenza virus 5 (PIV5), known as SER, requires a l

61 The strain diversity of a rubulavirus, parainfluenza virus 5 (PIV5), was investigated by compar

62 Previously, we developed two parainfluenza virus 5 (PIV5)-based RSV vaccine candidate

63 hesis that complement (C')-mediated lysis of parainfluenza virus 5 (PIV5)-infected cells would differ

64 , and cellular immunogenicity of intranasal, parainfluenza virus 5 (PIV5)-vectored COVID-19 vaccine C

65 Parainfluenza virus 5 (PIV5)-vectored intranasal COVID-1

66 We previously generated a parainfluenza virus 5 (PIV5)-vectored vaccine candidate

67 In this study, we evaluated two parainfluenza virus 5 (PIV5)-vectored vaccines expressin

68 Similar results were also observed with parainfluenza virus 5 (PIV5).

69 he FP of the F protein of the paramyxovirus, parainfluenza virus 5 (PIV5).

70 f the matrix (M) protein of a paramyxovirus, parainfluenza virus 5 (PIV5).

71 -3 as a binding partner for the M protein of parainfluenza virus 5 (PIV5).

72 this study, we show that vaccination with a parainfluenza virus 5 recombinant vaccine candidate expr

73 Simian parainfluenza virus 5 (SV5) is a prototype of the Paramy

74 sion (F) protein of the paramxyovirus simian parainfluenza virus 5 (SV5) promotes virus-cell and cell

75 on (F) protein from the paramyxovirus simian parainfluenza virus 5 (SV5) resulted in mutant F protein

76 ined the ability of the paramyxovirus simian parainfluenza virus 5 (SV5) to affect cell cycle progres

77 recently published prefusogenic structure of parainfluenza virus 5/SV5 F places CBF(2) in direct cont

78 ed "stalk exposure model" first proposed for parainfluenza virus 5 to other paramyxoviruses and propo

79 A parainfluenza virus 5-vectored vaccine expressing the na